Frequently Asked Questions

Perimenopause is the transition leading up to menopause, when estrogen and progesterone fluctuate before declining. It often begins in the mid-40s and can last several years. Menopause is the point confirmed after 12 consecutive months without a period, and the years that follow are postmenopause. Symptoms can appear at any stage, which is why knowing where you are matters.

The earliest signs are often a shift in your cycle, sleep that is no longer as deep, a shorter fuse, or energy that dips without explanation. Because these can begin years before periods stop, many women live with them without realizing the cause is hormonal. Recognizing the pattern early is what opens the most opportunity to manage it well.

Most commonly the 40s, though onset in the late 30s is within the normal clinical range. Because the average age of menopause in Canada is 51 and perimenopause can span several years, symptoms often begin well before most women connect them to hormones.

Typically two to ten years, varying considerably between individuals. The most disruptive symptoms often cluster in the period before the final menstrual period. Clinical assessment helps clarify where you are in the transition and what to expect.

Not always. Some ease once hormones stabilize, but others, including genitourinary changes, vasomotor symptoms, bone loss, and cardiovascular risk, can persist or become more prominent afterward. Postmenopausal health deserves the same clinical attention as the transition itself.

Often, yes. Fatigue in midlife tends to be multifactorial: estrogen and progesterone both influence sleep and energy, night sweats fragment your rest even when you do not fully wake, and shifting cortisol adds to the load. A thorough assessment separates the hormonal contributors from causes such as thyroid changes or anemia, which can coexist.

Yes. Difficulty with concentration, word recall, and short-term memory is well documented and reported by most women during the transition, reflecting estrogen's direct role in brain function. For most women, clarity improves as hormone levels stabilize. Symptoms that are severe or progressive are worth a clinical assessment.

For the great majority of women, no. The cognitive changes of perimenopause and menopause are usually temporary and tend to ease as hormones stabilize, and they are distinct from the progressive changes seen in dementia. Estrogen's relationship with long-term brain health is an active area of research, which is part of why understanding your individual picture in midlife is worthwhile. Symptoms that are persistent or worsening are always worth assessing, for clarity and reassurance.

For many women, yes. During perimenopause, fluctuating estrogen and declining progesterone affect the brain systems that regulate mood, which is why anxiety, irritability, and a sense of being more easily overwhelmed can appear or intensify, sometimes for the first time in your life. These changes are frequently hormonally driven but may co-exist with underlying mental health conditions. Clinical assessment helps distinguish them from anxiety or depression that may benefit from specific care approaches.

It can. Estrogen plays a role in joint and connective tissue, and as it declines, many women notice new stiffness or aches, often in the mornings or in the hands, sometimes called menopausal arthralgia. It is a recognized but frequently overlooked symptom, worth assessing alongside the wider hormonal picture rather than dismissing as simply getting older.

This is one of the most common experiences women describe, and it is understandable. Hormone levels fluctuate so much during the transition that a single result captures only one moment in a shifting picture, and standard reference ranges are not designed for it. Your symptoms are often the most meaningful clinical information at this stage. Specialist assessment reads your results in the context of your full history and experience, rather than against a population average.

Yes. Ovulation continues intermittently until menopause is confirmed, so pregnancy remains possible and contraception should be maintained if it is not desired. Many women are surprised by this, and it is worth a clear conversation as part of the bigger picture.

Often, yes. Genitourinary symptoms, including dryness, discomfort, and changes in bladder function or intimacy, tend to be progressive after menopause, because they are driven by declining estrogen in those tissues. They are common, very treatable, and too often endured in silence. There is no need to simply live with them.

Estrogen protects bone, so its decline accelerates bone loss in the years around and after menopause, raising the risk of osteoporosis and fracture over time. Because early bone loss has no symptoms, this is an important window for assessment and prevention, rather than waiting for a problem to appear.

Cardiovascular risk does rise after menopause. As estrogen declines, changes in cholesterol, blood pressure, and insulin sensitivity can shift the picture, and heart disease is the leading cause of death in women. The encouraging part is how much is modifiable: nutrition, physical activity, and clinical management of individual risk factors all make a meaningful difference, and midlife is the ideal time to address them. Menopause hormone therapy is not prescribed to prevent heart disease, though cardiovascular health is an important consideration in any individualized plan.

RoseWell provides care across the arc of perimenopause, menopause, and beyond: hormone-related and vasomotor symptoms, sleep, mood and emotional health, sexual and vaginal health, metabolic health and body composition, and long-term priorities including bone, heart, and brain health. Care is structured around four pillars: Hormone Intelligence, Metabolic and Lifestyle Foundations, Resilience and Restoration, and Longevity and Vitality.